exRNAdisease

Entry Detail

---



General Information

Database ID: exR0274628 RNA Name: hsa-miR-206 RNA Type: miRNA Chromosome: chr6 Starnd: + Coordinate: Start Site(bp): 52144401 End Site(bp): 52144422 External Links: hsa-miR-206

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE22981 Description: Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: Early satge breast cancer Case Sample: Breast Cancer Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand CAPNS1 chr19 36139953 36150353 + NPEPPS chr17 47522942 47623276 + SPRED1 chr15 38252836 38357249 + SLC30A7 chr1 100896076 100981757 + DDX5 chr17 64498254 64508199 - TRIM2 chr4 153152342 153339317 + DLG3 chrX 70444835 70505490 + LASP1 chr17 38869859 38921770 + RTL8B chrX 135020513 135022542 - FOXP1 chr3 70952817 71583993 - SDCBP chr8 58552924 58582859 + NME1-NME2 chr17 51153590 51171744 + NR2C2 chr3 14947584 15053600 + TNRC6B chr22 40044817 40335808 + CREB3L2 chr7 137874979 138002086 - NETO2 chr16 47077703 47143945 - ZNF518A chr10 96129715 96205288 + PGM2 chr4 37826660 37862937 + PRR12 chr19 49591182 49626439 + PTBP1 chr19 797075 812327 + CALM1 chr14 90396502 90408268 + NME2 chr17 51165435 51171747 + AP1S1 chr7 101154456 101161596 + MAPK1 chr22 21754500 21867680 - GID4 chr17 18039408 18068405 + SMCO4 chr11 93478472 93543391 - SS18 chr18 26016253 26091217 - CWC15 chr11 94962620 94973586 - WIPF2 chr17 40219304 40284136 + WDR5 chr9 134135365 134159968 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000816 chr17 80521229 80526077 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC005332.7 chr17 68188547 68189165 + AC145207.5 chr17 81878425 81881106 - LINC00641 chr14 21200079 21206900 - MALAT1 chr11 65497688 65506516 + MIR4435-2HG chr2 111006015 111523376 - NEAT1 chr11 65422774 65445540 + RMRP chr9 35657751 35658018 - Display:

Experiment Detail

GEO ID: GSE22981 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 801 Sample treatment protocol: NA RNA Extract protocol: Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications. RNA library preparation protocol: Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).

Reference

PMID: 21060830 Title: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer Author: Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer. Journal: PLoS One. 2010 Oct 29;5(10):e13735. Description: The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.